company background image
IART

Integra LifeSciences HoldingsNasdaqGS:IART Stock Report

Last Price

US$67.44

Market Cap

US$5.8b

7D

0.4%

1Y

-1.3%

Updated

18 Jan, 2022

Data

Company Financials +
IART fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance5/6
Financial Health3/6
Dividends0/6

IART Stock Overview

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.

Integra LifeSciences Holdings Competitors

Intuitive Surgical

NasdaqGS:ISRG

US$109.9b

Stryker

NYSE:SYK

US$100.6b

Becton Dickinson

NYSE:BDX

US$74.9b

Edwards Lifesciences

NYSE:EW

US$73.8b

Price History & Performance

Summary of all time highs, changes and price drops for Integra LifeSciences Holdings
Historical stock prices
Current Share PriceUS$67.44
52 Week HighUS$77.40
52 Week LowUS$61.85
Beta1.2
1 Month Change2.48%
3 Month Change-3.40%
1 Year Change-1.34%
3 Year Change46.70%
5 Year Change63.10%
Change since IPO1,358.16%

Recent News & Updates

Jan 01
An Intrinsic Calculation For Integra LifeSciences Holdings Corporation (NASDAQ:IART) Suggests It's 21% Undervalued

An Intrinsic Calculation For Integra LifeSciences Holdings Corporation (NASDAQ:IART) Suggests It's 21% Undervalued

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Integra LifeSciences...

Dec 19
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Nov 23
I Ran A Stock Scan For Earnings Growth And Integra LifeSciences Holdings (NASDAQ:IART) Passed With Ease

I Ran A Stock Scan For Earnings Growth And Integra LifeSciences Holdings (NASDAQ:IART) Passed With Ease

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Shareholder Returns

IARTUS Medical EquipmentUS Market
7D0.4%-1.5%-0.3%
1Y-1.3%3.8%13.7%

Return vs Industry: IART underperformed the US Medical Equipment industry which returned 3.8% over the past year.

Return vs Market: IART underperformed the US Market which returned 13.7% over the past year.

Price Volatility

Is IART's price volatile compared to industry and market?
IART volatility
IART Average Weekly Movement4.7%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: IART is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: IART's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19893,700Jan De Wittehttps://www.integralife.com

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Integra LifeSciences Holdings Fundamentals Summary

How do Integra LifeSciences Holdings's earnings and revenue compare to its market cap?
IART fundamental statistics
Market CapUS$5.83b
Earnings (TTM)US$216.44m
Revenue (TTM)US$1.53b

26.4x

P/E Ratio

3.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IART income statement (TTM)
RevenueUS$1.53b
Cost of RevenueUS$549.81m
Gross ProfitUS$975.76m
ExpensesUS$759.32m
EarningsUS$216.44m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 23, 2022

Earnings per share (EPS)2.56
Gross Margin63.96%
Net Profit Margin14.19%
Debt/Equity Ratio98.4%

How did IART perform over the long term?

See historical performance and comparison

Valuation

Is Integra LifeSciences Holdings undervalued compared to its fair value and its price relative to the market?

21.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IART ($68.79) is trading below our estimate of fair value ($85.42)

Significantly Below Fair Value: IART is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: IART is good value based on its PE Ratio (26.9x) compared to the US Medical Equipment industry average (47.8x).

PE vs Market: IART is poor value based on its PE Ratio (26.9x) compared to the US market (17.4x).


Price to Earnings Growth Ratio

PEG Ratio: IART is poor value based on its PEG Ratio (3x)


Price to Book Ratio

PB vs Industry: IART's PB Ratio (3.6x) is in line with the US Medical Equipment industry average.


Future Growth

How is Integra LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

8.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IART's forecast earnings growth (8.9% per year) is above the savings rate (2%).

Earnings vs Market: IART's earnings (8.9% per year) are forecast to grow slower than the US market (13% per year).

High Growth Earnings: IART's earnings are forecast to grow, but not significantly.

Revenue vs Market: IART's revenue (6.1% per year) is forecast to grow slower than the US market (9.3% per year).

High Growth Revenue: IART's revenue (6.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IART's Return on Equity is forecast to be low in 3 years time (14.8%).


Past Performance

How has Integra LifeSciences Holdings performed over the past 5 years?

21.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IART has high quality earnings.

Growing Profit Margin: IART's current net profit margins (14.2%) are higher than last year (4.1%).


Past Earnings Growth Analysis

Earnings Trend: IART's earnings have grown significantly by 21.6% per year over the past 5 years.

Accelerating Growth: IART's earnings growth over the past year (283.3%) exceeds its 5-year average (21.6% per year).

Earnings vs Industry: IART earnings growth over the past year (283.3%) exceeded the Medical Equipment industry 51.2%.


Return on Equity

High ROE: IART's Return on Equity (13.3%) is considered low.


Financial Health

How is Integra LifeSciences Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IART's short term assets ($1.1B) exceed its short term liabilities ($332.9M).

Long Term Liabilities: IART's short term assets ($1.1B) do not cover its long term liabilities ($1.8B).


Debt to Equity History and Analysis

Debt Level: IART's net debt to equity ratio (69.6%) is considered high.

Reducing Debt: IART's debt to equity ratio has increased from 83.5% to 98.4% over the past 5 years.

Debt Coverage: IART's debt is well covered by operating cash flow (20.1%).

Interest Coverage: IART's interest payments on its debt are well covered by EBIT (5.8x coverage).


Balance Sheet


Dividend

What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IART's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IART's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IART's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IART's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IART's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Jan De Witte (57 yo)

0.083

Tenure

Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 2021. He had been the Chief Executive Officer at Barco NV since September...


Leadership Team

Experienced Management: IART's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: IART's board of directors are considered experienced (8.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IART insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Integra LifeSciences Holdings Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Integra LifeSciences Holdings Corporation
  • Ticker: IART
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$5.826b
  • Shares outstanding: 84.70m
  • Website: https://www.integralife.com

Number of Employees


Location

  • Integra LifeSciences Holdings Corporation
  • 1100 Campus Road
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/18 23:14
End of Day Share Price2022/01/18 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.